2型糖尿病患者双倍或三倍剂量每周一次胰岛素icodec与每日一次甘精胰岛素U100的低血糖频率及生理反应比较:一项随机交叉试验
该随机、单中心、开放标签、两周期交叉试验在2型糖尿病患者中比较了双倍或三倍剂量每周一次icodec与每日一次甘精胰岛素U100的低血糖频率、发生时间及恢复情况。结果显示,双倍或三倍剂量icodec与甘精胰岛素U100的低血糖风险相似,低血糖期间icodec引起的症状反应相当且内分泌反应略强。
要点
- 双倍或三倍剂量icodec与甘精胰岛素U100的临床显著低血糖比例无显著差异。
- 三倍剂量后血糖最低值≤2.5 mmol/l的比例甘精胰岛素U100高于icodec。
- 三倍剂量后低血糖期间icodec的肾上腺素和皮质醇反应大于甘精胰岛素U100。
核心结论
- 双倍或三倍剂量每周一次icodec与双倍或三倍剂量每日一次甘精胰岛素U100的低血糖风险相似。
- 低血糖期间,icodec与甘精胰岛素U100相比引起相当的症状反应和略强的内分泌反应。
研究设计与样本
- 随机、单中心(奥地利格拉茨医科大学内科学系内分泌与糖尿病科)、开放标签、两周期交叉试验。
- 2型糖尿病患者(年龄18-72岁,BMI 18.5-37.9 kg/m2,HbA1c ≤75 mmol/mol [≤9.0%])接受基础胰岛素伴或不伴口服降糖药治疗。
- 受试者接受每周一次icodec(6周)和每日一次甘精胰岛素U100(11天),总周剂量基于run-in期每日甘精胰岛素U100个体化滴定(目标空腹血浆葡萄糖4.4-7.2 mmol/l)等摩尔计算。
- 稳态时给予双倍和三倍剂量icodec及甘精胰岛素U100后诱导低血糖:先以可变静脉葡萄糖输注维持血糖正常于5.5 mmol/l,然后终止葡萄糖输注使血糖降至不低于2.5 mmol/l(目标血糖最低值),维持15分钟,再以恒定静脉葡萄糖(5.5 mg kg-1 min-1)恢复血糖正常。
主要发现
- 双倍剂量后临床显著低血糖(血糖最低值<3.0 mmol/l)发生率icodec组17例(39.5%)vs甘精胰岛素U100组15例(35.7%),p=0.63;三倍剂量后icodec组20例(52.6%)vs甘精胰岛素U100组28例(70.0%),p=0.14。
- 血糖从5.5 mmol/l降至3.0 mmol/l的时间无统计学显著治疗差异(双倍剂量后2.9-4.5小时,三倍剂量后2.2-2.4小时)。
- 血糖最低值≤2.5 mmol/l的比例双倍剂量后icodec组2例(4.7%)vs甘精胰岛素U100组3例(7.1%),p=0.63;三倍剂量后icodec组1例(2.6%)vs甘精胰岛素U100组10例(25.0%),p=0.03。
- 恒定静脉葡萄糖输注恢复低血糖在所有治疗中均<30分钟。
- 三倍剂量后,icodec vs甘精胰岛素U100在血糖3.0 mmol/l时肾上腺素治疗比2.54(95%CI 1.69, 3.82),p<0.001;皮质醇在血糖3.0 mmol/l时治疗比1.64(95%CI 1.13, 2.38),p=0.01;在血糖最低值时治疗比1.80(95%CI 1.09, 2.97),p=0.02。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This study compared the frequency of hypoglycaemia, time to hypoglycaemia and recovery from hypoglycaemia after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100. Furthermore, the symptomatic and counterregulatory responses to hypoglycaemia were compared between icodec and glargine U100 treatment. METHODS: In a randomised, single-centre (Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria), open-label, two-period crossover trial, individuals with type 2 diabetes (age 18-72 years, BMI 18.5-37.9 kg/m2, HbA1c ≤75 mmol/mol [≤9.0%]) treated with basal insulin with or without oral glucose-lowering drugs received once-weekly icodec (for 6 weeks) and once-daily glargine U100 (for 11 days). Total weekly doses were equimolar based on individual titration of daily glargine U100 during the run-in period (target fasting plasma glucose [PG]: 4.4-7.2 mmol/l). Randomisation was carried out by assigning a randomisation number to each participant in ascending order, which encoded to one of two treatment sequences via a randomisation list prepared prior to the start of the trial. At steady state, double and triple doses of icodec and glargine U100 were administered followed by hypoglycaemia induction: first, euglycaemia was maintained at 5.5 mmol/l by variable i.v. infusion of glucose; glucose infusion was then terminated, allowing PG to decrease to no less than 2.5 mmol/l (target PGnadir). The PGnadir was maintained for 15 min. Euglycaemia was restored by constant i.v. glucose (5.5 mg kg-1 min-1). Hypoglycaemic symptoms score (HSS), counterregulatory hormones, vital signs and cognitive function were assessed at predefined PG levels towards the PGnadir. RESULTS: Hypoglycaemia induction was initiated in 43 and 42 participants after double dose of icodec and glargine U100, respectively, and in 38 and 40 participants after triple doses, respectively. Clinically significant hypoglycaemia, defined as PGnadir <3.0 mmol/l, occurred in comparable proportions of individuals treated with icodec vs glargine U100 after double (17 [39.5%] vs 15 [35.7%]; p=0.63) and triple (20 [52.6%] vs 28 [70.0%]; p=0.14) doses. No statistically significant treatment differences were observed in the time to decline from PG values of 5.5 mmol/l to 3.0 mmol/l (2.9-4.5 h after double dose and 2.2-2.4 h after triple dose of the insulin products). The proportion of participants with PGnadir ≤2.5 mmol/l was comparable between treatments after double dose (2 [4.7%] for icodec vs 3 [7.1%] for glargine U100; p=0.63) but higher for glargine U100 after triple dose (1 [2.6%] vs 10 [25.0%]; p=0.03). Recovery from hypoglycaemia by constant i.v. glucose infusion took <30 min for all treatments. Analyses of the physiological response to hypoglycaemia only included data from participants with PGnadir <3.0 mmol/l and/or the presence of hypoglycaemic symptoms; in total 20 (46.5%) and 19 (45.2%) individuals were included after a double dose of icodec and glargine U100, respectively, and 20 (52.6%) and 29 (72.5%) individuals were included after a triple dose of icodec and glargine U100, respectively. All counterregulatory hormones (glucagon, adrenaline [epinephrine], noradrenaline [norepinephrine], cortisol and growth hormone) increased during hypoglycaemia induction with both insulin products at both doses. Following triple doses, the hormone response was greater with icodec vs glargine U100 for adrenaline at PG3.0 mmol/l (treatment ratio 2.54 [95% CI 1.69, 3.82]; p<0.001), and cortisol at PG3.0 mmol/l (treatment ratio 1.64 [95% CI 1.13, 2.38]; p=0.01) and PGnadir (treatment ratio 1.80 [95% CI 1.09, 2.97]; p=0.02). There were no statistically significant treatment differences in the HSS, vital signs and cognitive function. CONCLUSIONS/INTERPRETATION: Double or triple doses of once-weekly icodec lead to a similar risk of hypoglycaemia compared with double or triple doses of once-daily glargine U100. During hypoglycaemia, comparable symptomatic and moderately greater endocrine responses are elicited by icodec vs glargine U100. TRIAL REGISTRATION: ClinicalTrials.gov NCT03945656. FUNDING: This study was funded by Novo Nordisk A/S.
引用
- Pieber TR, Arfelt KN, Cailleteau R, et al. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Diabetologia. 2023. PMID: 37308751. doi:10.1007/s00125-023-05921-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。